TROXERUTINA KERN PHARMA 100 mg/ml SOLUCION ORAL EFG Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

troxerutina kern pharma 100 mg/ml solucion oral efg

kern pharma s.l. - troxerutina - soluciÓn oral - 100 mg/ml - troxerutina 100 mg - troxerutina

IMBRUVICA 140 MG TABLETS Israel - engelsk - Ministry of Health

imbruvica 140 mg tablets

j-c health care ltd - ibrutinib - film coated tablets - ibrutinib 140 mg - ibrutinib - • mantle cell lymphoma:imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.• chronic lymphocytic leukemia/small lymphocytic lymphoma :imbruvica is indicated for the treatment of adult patients, with chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll)• chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion:imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion.• waldenström’s macroglobulinemiaimbruvica is indicated for the treatment of adult patients with waldenström’s macroglobulinemia (wm).• marginal zone lymphomaimbruvica is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who require systemic therapy and have received at least one prior anti-cd20-based therapy.• chronic graft versus host diseaseimbruvica is indicated for the treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy.

IMBRUVICA 280 MG TABLETS Israel - engelsk - Ministry of Health

imbruvica 280 mg tablets

j-c health care ltd - ibrutinib - film coated tablets - ibrutinib 280 mg - ibrutinib - • mantle cell lymphoma:imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.• chronic lymphocytic leukemia/small lymphocytic lymphoma :imbruvica is indicated for the treatment of adult patients, with chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll)• chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion:imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion.• waldenström’s macroglobulinemiaimbruvica is indicated for the treatment of adult patients with waldenström’s macroglobulinemia (wm).• marginal zone lymphomaimbruvica is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who require systemic therapy and have received at least one prior anti-cd20-based therapy.• chronic graft versus host diseaseimbruvica is indicated for the treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy.

IMBRUVICA 420 MG TABLETS Israel - engelsk - Ministry of Health

imbruvica 420 mg tablets

j-c health care ltd - ibrutinib - film coated tablets - ibrutinib 420 mg - ibrutinib - • mantle cell lymphoma:imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.• chronic lymphocytic leukemia/small lymphocytic lymphoma :imbruvica is indicated for the treatment of adult patients, with chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll)• chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion:imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion.• waldenström’s macroglobulinemiaimbruvica is indicated for the treatment of adult patients with waldenström’s macroglobulinemia (wm).• marginal zone lymphomaimbruvica is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who require systemic therapy and have received at least one prior anti-cd20-based therapy.• chronic graft versus host diseaseimbruvica is indicated for the treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy.

IMBRUVICA 560 MG TABLETS Israel - engelsk - Ministry of Health

imbruvica 560 mg tablets

j-c health care ltd - ibrutinib - film coated tablets - ibrutinib 560 mg - ibrutinib - • mantle cell lymphoma:imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.• chronic lymphocytic leukemia/small lymphocytic lymphoma :imbruvica is indicated for the treatment of adult patients, with chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll)• chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion:imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion.• waldenström’s macroglobulinemiaimbruvica is indicated for the treatment of adult patients with waldenström’s macroglobulinemia (wm).• marginal zone lymphomaimbruvica is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who require systemic therapy and have received at least one prior anti-cd20-based therapy.• chronic graft versus host diseaseimbruvica is indicated for the treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy.

VARILIV TROXERUTINA 1 g GRANULADO PARA SOLUCION ORAL Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

variliv troxerutina 1 g granulado para solucion oral

laboratorios cinfa s.a. - troxerutina - granulado para soluciÓn oral - 1.000 mg - troxerutina 1000 mg - troxerutina

TROXERUTINA NORMON 100 mg/ml SOLUCION ORAL EFG Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

troxerutina normon 100 mg/ml solucion oral efg

laboratorios normon, s.a. - troxerutina - excipientes: sacarina sodica,sorbato potasico,parahidroxibenzoato de metilo,parahidroxibenzoato de propilo,propilenglicol - agentes estabilizadores de capilares - bioflavoniodes - troxerutina

TROXERUTINA NORMON 1000 mg GRANULADO PARA SOLUCION ORAL Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

troxerutina normon 1000 mg granulado para solucion oral

laboratorios normon, s.a. - troxerutina - excipientes: sacarina sodica,isomalta - agentes estabilizadores de capilares - bioflavoniodes - troxerutina

TROXERUTINA PENSA 100 mg/ml SOLUCION ORAL EFG Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

troxerutina pensa 100 mg/ml solucion oral efg

pensa pharma, s.a.u - troxerutina - excipientes: propilenglicol,parahidroxibenzoato de metilo,parahidroxibenzoato de propilo,sorbato potasico,sacarina sodica - agentes estabilizadores de capilares - bioflavoniodes - troxerutina

TROXERUTINE BIOGARAN CONSEIL 3,5 g, poudre pour solution buvable en sachet-dose Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

troxerutine biogaran conseil 3,5 g, poudre pour solution buvable en sachet-dose

biogaran - troxérutine 3 - poudre - 3,5 g - pour un sachet-dose > troxérutine 3,5 g - vasculoprotecteur - médicament agissant sur les capillaires - classe pharmacothérapeutique - code atc : c05ca04.ce médicament est un veinotonique (il augmente la tonicité des parois veineuses) et un vasculoprotecteur (il augmente la résistance des petits vaisseaux sanguins).ce médicament est indiqué dans les troubles de la circulation veineuse (jambes lourdes, douleurs, sensations pénibles dites « impatiences » lors du coucher) et dans la crise hémorroïdaire (douleurs, sensation de congestion).